- Home
- IGC vs ADVB Comparison
IGC vs ADVB Comparison
Compare IGC & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- ADVB
- Stock Information
- Founded
- IGC 2005
- ADVB 2014
- Country
- IGC United States
- ADVB United States
- Employees
- IGC N/A
- ADVB N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- IGC Health Care
- ADVB Health Care
- Exchange
- IGC Nasdaq
- ADVB Nasdaq
- Market Cap
- IGC 20.2M
- ADVB 20.8M
- IPO Year
- IGC N/A
- ADVB 2025
- Fundamental
- Price
- IGC $0.31
- ADVB $0.69
- Analyst Decision
- IGC Strong Buy
- ADVB
- Analyst Count
- IGC 2
- ADVB 0
- Target Price
- IGC $3.88
- ADVB N/A
- AVG Volume (30 Days)
- IGC 230.9K
- ADVB 57.0K
- Earning Date
- IGC 08-07-2025
- ADVB 08-03-2025
- Dividend Yield
- IGC N/A
- ADVB N/A
- EPS Growth
- IGC N/A
- ADVB N/A
- EPS
- IGC N/A
- ADVB N/A
- Revenue
- IGC $1,236,000.00
- ADVB N/A
- Revenue This Year
- IGC N/A
- ADVB N/A
- Revenue Next Year
- IGC $16.45
- ADVB N/A
- P/E Ratio
- IGC N/A
- ADVB N/A
- Revenue Growth
- IGC 1.65
- ADVB N/A
- 52 Week Low
- IGC $0.25
- ADVB $0.69
- 52 Week High
- IGC $0.55
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- IGC 49.31
- ADVB N/A
- Support Level
- IGC $0.30
- ADVB N/A
- Resistance Level
- IGC $0.32
- ADVB N/A
- Average True Range (ATR)
- IGC 0.02
- ADVB 0.00
- MACD
- IGC -0.00
- ADVB 0.00
- Stochastic Oscillator
- IGC 20.00
- ADVB 0.00
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.